NCT04004325 - A Study of FT 4101 in Overweight/Obese Participants With Non-alcoholic Steatohepatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 17, 2019

Primary Completion Date

January 20, 2020

Study Completion Date

January 20, 2020

Conditions

Nonalcoholic Steatohepatitis (NASH)Overweight or Obesity

Interventions

DRUG

FT-4101

FT-4101 will be supplied as active capsules and will be administered per the protocol defined frequency and dose level.

DRUG

FT-4101 placebo

FT-4101 placebo will be supplied as placebo capsule matching in size and color to all the active capsules and will be administered per the protocol defined frequency and dose level.

OTHER

Deuterated Water

Deuterated water will be provided as individual ready-to-use, single dose bottles each containing 50 mL of deuterated water (70%).

Trial Locations (2)

91763

Catalina Research Institute, Montclair

91911

ProSciento, Inc., Chula Vista